TransMedics Group (NASDAQ:TMDX) Trading Up 5.3% – Here’s What Happened

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price traded up 5.3% during mid-day trading on Tuesday . The company traded as high as $95.67 and last traded at $93.81. 241,684 shares were traded during mid-day trading, a decline of 75% from the average session volume of 950,997 shares. The stock had previously closed at $89.11.

Analyst Ratings Changes

A number of equities research analysts have recently commented on TMDX shares. Canaccord Genuity Group lowered their target price on TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. Robert W. Baird lowered their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Needham & Company LLC reduced their target price on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Stephens lifted their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Stock Up 1.4 %

The stock has a fifty day simple moving average of $129.09 and a two-hundred day simple moving average of $139.89. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market cap of $3.11 billion, a PE ratio of 98.65 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter last year, the firm earned ($0.12) earnings per share. The firm’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 36,958 shares of company stock worth $5,230,528. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its holdings in TransMedics Group by 35.1% in the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company’s stock worth $1,286,000 after buying an additional 4,518 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of TransMedics Group by 337,462.5% in the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after purchasing an additional 26,997 shares during the period. ProShare Advisors LLC boosted its position in shares of TransMedics Group by 7.8% during the first quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock valued at $434,000 after purchasing an additional 427 shares in the last quarter. Entropy Technologies LP purchased a new stake in TransMedics Group in the first quarter worth $201,000. Finally, State Board of Administration of Florida Retirement System raised its holdings in TransMedics Group by 8.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock worth $745,000 after purchasing an additional 780 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.